-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Cero Therapeutics Holdings, Inc. quarterly Deferred Federal Income Tax Expense (Benefit) history and growth rate for Q1 2023.
- Cero Therapeutics Holdings, Inc. Deferred Federal Income Tax Expense (Benefit) for the quarter ending May 9, 2023 was $182K.
Deferred Federal Income Tax Expense (Benefit), Quarterly (USD)